THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) THR325ILE AND FACTOR XII C46T POLYMORPHISMS IN ATHEROSCLEROTIC RENAL ARTERY STENOSIS

Abstract number: P-M-388

Smid¹ M., Plat² A.W., Stoffers² H.E.J.H., Spronk¹ H.M.H., de Leeuw³ P.W., Kroon³ A.A., ten Cate¹ H.

¹¹Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht ²²Department of General Practice, Maastricht University ³³Department of Internal Medicine, University Hospital, Maastricht, Netherlands

How-to-cite Smid M, Plat AW, Stoffers HEJH, Spronk HMH, de Leeuw PW, Kroon AA, ten Cate H. THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) THR325ILE AND FACTOR XII C46T POLYMORPHISMS IN ATHEROSCLEROTIC RENAL ARTERY STENOSIS. J Thromb Haemost 2007; 5 Supplement 2: P-M-388

Abstract

Introduction: Atherosclerotic renal artery stenosis is the most important cause of secondary hypertension. Fibrinolytic proteins may be involved in vessel wall remodelling, associated with atherosclerosis. The influence of specific polymorphisms in Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and Factor XII, regulators of fibrinolysis, on atherosclerotic renal artery disease is unknown. We investigated the association of the TAFI Thr325Ile and the Factor XII C46T polymorphims with the presence of atherosclerotic renal artery stenosis.

Methods: 49 patients with angiographically proven atherosclerotic renal artery stenosis were selected from consecutive patients, referred to the Internal Medicine outpatients clinic because of the suspicion of having renal artery stenosis. From a family practice 345 normotensive and 376 hypertensive controls were selected as controls. Genotyping was performed by PCR and restriction fragment length analysis. Hypertension guidelines for Dutch general practitioners were used for the diagnosis of hypertension.

Results: TAFI 325 Thr/Thr, Thr/Ile and Ile/Ile genotypes occurred 53%, 39%, and 8% in the renal artery stenosis group compared to 51%, 38%, and 10% in hypertensive controls and 51%, 37%, and 12% in normotensive controls. Factor XII 46 CC, CT and TT genotypes were 51%, 43% and 7% in the renal artery stenosis group, 51%, 39% and 10% in hypertensive controls and 51%, 39% and 10% in normotensive controls.

Conclusions: The TAFI Thr325Ile and the Factor XII C46T polymorphisms are not associated with the presence of atherosclerotic renal artery stenosis.

To cite this abstract use the following format:

Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number

Session Details

Date:	01/08/2007
Time:	00:00-00:00
Session name:	XXIst ISTH Congress
Subject:
Location:	Oxford, UK
Presentation type:
Back to top